sponsored
PatientsVille.com Logo

PatientsVille

Metastases To Bladder Medical Research Studies

Up-to-date List of Metastases To Bladder Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Metastases To Bladder Medical Research Studies

Rank Status Study
1 Recruiting Neuropharmacokinetics of Eribulin Mesylate in Treating Patients With Brain Metastases From Breast, Bladder, or Non-small Cell Lung Cancer
Conditions: Breast Carcinoma Metastatic to the Brain;   Lung Carcinoma Metastatic to the Brain;   Metastatic Malignant Neoplasm to the Adult Brain;   Stage IV Bladder Cancer;   Stage IV Non-Small Cell Lung Cancer
Interventions: Procedure: Therapeutic Conventional Surgery;   Procedure: Biopsy;   Drug: Eribulin Mesylate;   Procedure: Microdialysis;   Other: Pharmacological Study
Outcome Measures: Time of maximum concentration observed (Tmax) for eribulin mesylate;   Maximum concentration observed (Cmax) for eribulin mesylate;   Area under the curve (AUC) for eribulin mesylate;   Half-life (t1/2) for eribulin mesylate;   Ratio of AUC of eribulin mesylate in dialysate to plasma;   Toxicity profile of eribulin mesylate graded using the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0;   Clinical benefit rate defined as tumor response on brain MRI results
2 Recruiting Study of Ferumoxytol Enhanced MRI for Detecting Lymph Node Metastases in Prostate, Bladder, and Kidney Cancers
Conditions: Prostate Cancer;   Bladder Cancer;   Kidney Cancer
Intervention: Drug: Ferumoxytol
Outcome Measures: Compare the difference in signal between metastatic and normal nodes;   Optimal timing for imaging;   Difference in signal within metastatic nodes
3 Recruiting Prophylactic Cranial Irradiation (PCI) for Small Cell Carcinoma of the Urothelium
Condition: Bladder Cancer
Interventions: Radiation: Prophylactic Cranial Irradiation (PCI);   Other: Brain X-ray
Outcome Measure: Brain Metastasis Free Survival
4 Recruiting Characterization of Circulating Tumor Cells Captured by c-MET (CTC-MET)
Conditions: Prostate Cancer;   Renal Cell Carcinoma;   Bladder Cancer;   Colorectal Cancer;   Gastric Cancer;   Pancreatic Cancer;   Non-small Cell Lung Cancer
Interventions: Device: Mesenchymal-marker based ferrofluid (c-MET);   Device: Epithelial cell adhesion molecule (EpCAM) ferrofluid
Outcome Measures: Feasibility;   Difference in the median number of CTCs;   Association of the number of detectable CTCs with baseline clinical and pathologic disease characteristics.;   Kinetics of CTCs over time during treatment with c-MET targeted therapies
5 Recruiting Secondary Bilateral Sacral Nerve Stimulation in Overactive Bladder Patients
Condition: Bladder Hyperactivity
Intervention: Device: Device:   INTERSTIM II
Outcome Measures: Success of Test Period;   Effect of alone controlateral stimulation
6 Not yet recruiting The Association Between Alpha 1 Acid Glycoprotein Level and Outcome Metastatic Cancer Treated With Docetaxel
Conditions: Metastatic Lung Cancer;   Metastatic Breast Cancer;   Metastatic Gastric Cancer;   Metastatic Prostate Cancer;   Metastatic Bladder Cancer
Intervention:
Outcome Measures: The association between the baseline plasma level of alpha 1 acid glycoprotein and progression free survival of docetaxel based therapy in patients with metastatic cancer;   The association between the baseline plasma level of alpha 1 acid glycoprotein and the response rate and overall survival of docetaxel based therapy in patients with metastatic cancer
7 Unknown  Botox for the Treatment of Overactive Bladder Secondary to Benign Prostatic Obstruction
Condition: Overactive Bladder
Intervention: Drug: Botox/Placebo
Outcome Measure: The primary efficacy Parameter is frequency of micturition (3-day voiding diary)
8 Recruiting Surgery With or Without Postoperative Intensity Modulated Radiation Therapy in Treating Patients With Urothelial Bladder Cancer
Conditions: Stage III Bladder Cancer;   Stage IV Bladder Cancer
Interventions: Procedure: therapeutic conventional surgery;   Radiation: intensity-modulated radiation therapy
Outcome Measures: Pelvic recurrence (PR), defined as soft tissue tumor recurrence in the pelvis anywhere between the L5-S1 disc space superiorly and the pelvic floor inferiorly, taking into account distant metastases or death as competing risks;   Disease free survival (DFS), defined as the first occurrence of either: pelvic failure, distant metastasis, or death;   Incidence of acute radiation bowel toxicity, scored using the Common Terminology Criteria for Adverse Events (CTCAE) version (v)4.0;   Incidence of late radiation bowel toxicity, scored using the CTCAE v4.0
9 Unknown  This is a Prospective, Randomized, Double-Blind Study Comparing Intravesical Injection of Botox® to Placebo.
Condition: Overactive Bladder
Intervention: Drug: Botox
Outcome Measures: Safety and efficacy of BOTOX to placebo (saline) in the treatment of OAB secondary to BPO.;   Patient satisfaction to intradetrussor injection of Botox versus placebo.
10 Recruiting Collecting and Studying Blood and Tissue Samples From Patients With Locally Recurrent or Metastatic Prostate or Bladder/Urothelial Cancer
Conditions: Healthy Control;   Localized Urothelial Carcinoma of the Renal Pelvis and Ureter;   Metastatic Malignant Neoplasm in the Bone;   Metastatic Malignant Neoplasm in the Soft Tissues;   Metastatic Urothelial Carcinoma of the Renal Pelvis and Ureter;   Recurrent Bladder Carcinoma;   Recurrent Prostate Carcinoma;   Recurrent Urothelial Carcinoma of the Renal Pelvis and Ureter;   Stage IV Bladder Cancer;   Stage IV Bladder Urothelial Carcinoma;   Stage IV Prostate Cancer
Interventions: Other: Cytology Specimen Collection Procedure;   Other: Laboratory Biomarker Analysis
Outcome Measures: DNA genomic sequencing;   Gene expression profile using microarray assays;   Mutation mapping using the OncoMap and other genotyping techniques;   Expression of androgen metabolic enzymes by quantitative real time-polymerase chain reaction;   Proteomic profile
11 Unknown  Hyperbaric Oxygen Therapy in Treating Long-Term Gastrointestinal Adverse Effects Caused by Radiation Therapy in Patients With Pelvic Cancer
Conditions: Bladder Cancer;   Cervical Cancer;   Colorectal Cancer;   Endometrial Cancer;   Gastrointestinal Complications;   Long-term Effects Secondary to Cancer Therapy in Adults;   Ovarian Cancer;   Prostate Cancer;   Radiation Toxicity;   Sarcoma;   Testicular Germ Cell Tumor;   Vaginal Cancer
Interventions: Other: questionnaire administration;   Procedure: gastrointestinal complications management/prevention;   Procedure: quality-of-life assessment
Outcome Measures: Gastrointestinal symptoms score using the IBDQ quality-of-life questionnaire;   Physician assessment of adverse effects using LENT SOMA scales of radiation injury;   Patient self-assessments using EORTC QLQ-C30 and Defecation Problem Subscale of QLQ-CR38;   Photographic images of rectal mucosa;   Physician assessment of rectal dysfunction based on the modified CTCAE grading system;   Health economics data
12 Recruiting A Pilot Study of Mirabegron and Behavioral Modification Including Pelvic Floor Exercise for Overactive Bladder in Parkinson's Disease (MAESTRO)
Condition: Parkinsons Disease
Interventions: Drug: Mirabegron;   Drug: Placebo
Outcome Measures: Change in the mean daily Overactive Bladder-Symptom Composite Score.;   Secondary Outcome Measures based on clinic visits
13 Recruiting This is a Multinational Study Comparing the Efficacy and Safety of Two Medicines , Solifenacin Succinate and Mirabegron Taken Together, or Separately, or a Mock Treatment (Placebo) in Subjects With Symptoms of Overactive Bladder
Conditions: Overactive Bladder;   Urgency Incontinence;   Urinary Bladder Overactive;   Urinary Bladder DiseasesUrologic Diseases
Interventions: Drug: Solifenacin Succinate;   Drug: Mirabegron;   Drug: Placebo
Outcome Measures: Change from baseline in mean number of incontinence episodes per 24 hours at End of Treatment (EoT);   Change from baseline in mean number of micturitions per 24 hours at EoT;   Change from baseline in mean volume voided per micturition at EoT;   Change from baseline in Symptom Bother as assessed by Overactive Bladder Questionnaire (OAB-q) at EoT;   Change from baseline in Subject assessment of Treatment Satisfaction-Visual Analogue Scale (TS-VAS) at EoT;   Number of incontinence episodes during the 7-day observation period prior to week 4, 8, 12 and EoT and changes from baseline;   Change from baseline in mean number of incontinence episodes per 24 hours at secondary time points (after 4, 8 and 12 weeks of treatment);   Change from baseline in mean number of micturitions per 24 hours at secondary time points (after 4, 8 and 12 weeks of treatment);   Change from baseline in mean volume voided at secondary time points (after 4, 8 and 12 weeks of treatment);   Number of urgency incontinence episodes during the 7-day observation period prior to week 4, 8, 12 and EoT and changes from baseline;   Change from baseline in mean number of urgency incontinence episodes per 24 hours (Week 4, 8, 12, and EoT);   Change from baseline in mean number of urgency episodes (grade 3 and/or 4)/24 hours (PPIUS scale) (Week 4, 8, 12, and EoT);   Number of nocturia episodes during the 7-day observation period prior to Week 4, 8, 12, and EoT and changes from baseline;   Change from baseline in mean number of nocturia episodes per 24 hours(Week 4, 8, 12, and EoT);   Number of pads used during the 7-day observation period prior to Week 4, 8, 12, and EoT and changes from baseline;   Change from baseline in mean number of pads used per 24 hours (Week 4, 8, 12, and EoT);   Number of incontinence-free days during the 7-day diary period (Week 4, 8, 12, and EoT);   Number of days with less than 8 micturitions during the 7-day diary period (Week 4, 8, 12, and EoT);   Number of incontinence-free days with less than 8 micturitions per day during the 7-day diary period (Week 4, 8, 12, and EoT)
14 Recruiting Systemic Treatment of Resistant Metastatic Disease
Conditions: Non-small Cell Lung Cancer;   Castrate-resistant Prostate Cancer;   Melanoma;   Bladder Cancer
Intervention: Biological: CVA21
Outcome Measure: Response rate assessed according to immune-related RECIST 1.1 criteria
15 Not yet recruiting FIRBladd - Use of Infrared Spectroscopy in the Diagnosis of Bladder Tumors
Condition: Bladder Cancer
Intervention: Other: Urine infrared analysis
Outcome Measures: infrared spectroscopy;   TNM  system (tumor-nodes-metastasis)
16 Recruiting Adjuvant Radiation for High Risk Bladder Cancer
Conditions: Bladder Cancer;   Squamous Cell Carcinoma of the Bladder;   Stage III Bladder Cancer;   Stage IV Bladder Cancer;   Transitional Cell Carcinoma of the Bladder
Interventions: Radiation: 3D conformal radiation therapy;   Procedure: quality-of-life assessment;   Procedure: therapeutic conventional surgery
Outcome Measures: Gastrointestinal (GI) late effects, assessed using Radiation Therapy Oncology Group (RTOG) Late Effects in Normal Tissues (LENT)/Subjective, Objective, Management and Analytic (SOMA) scales;   Acute adverse events greater than grade 2, graded by CTCAE version 4.0;   Loco-regional failure, considered any failure in the treatment field of the pelvis;   Rate of distant metastases;   Rate of disease-free survival;   Overall survival rate;   Quality of life, assessed using FACT-BL
17 Unknown  External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases
Condition: Cancer
Interventions: Drug: indinavir sulfate;   Drug: ritonavir;   Radiation: radiation therapy
Outcome Measures: Time to treatment failure in the brain (TTF) as determined by the radiological response rate;   Overall survival (OS);   Radiological volumetric response to treatment;   Local intracranial disease progression at 4 months;   Progression-free survival at 6 months;   Improvement of symptoms;   Time to symptom relapse or symptom progression;   Duration of use of steroids;   Duration of use of anticonvulsive drugs
18 Unknown  PF-03446962 in Relapsed or Refractory Urothelial Cancer
Condition: Transitional Cell Carcinoma of Bladder
Intervention: Drug: PF03446962
Outcome Measures: Progression-free survival.;   Safety (CTCAE v.4.03);   RECIST response-rate;   Overall Survival;   Circulating and Tissue Biomarkers
19 Recruiting IMvigor 010 Study: Anti-Programmed Death-Ligand 1 (PD-L1) Antibody MPDL3280A Treatment Versus Observation as Adjuvant Therapy in Patients With PD-L1 Positive, High Risk Muscle Invasive Bladder Cancer After Cystectomy
Condition: Bladder Cancer, Cancer
Intervention: Biological: MPDL3280A
Outcome Measures: Disease-Free Survival (DFS);   Overall Survival (OS);   Disease-Specific Survival (DSS);   Distant Metastasis-Free Survival (DMFS);   Number of Participants with Adverse Events (AEs);   Percentage of Anti-Therapeutic Antibody (ATA) Response to MPDL3280A;   Maximum Observed Serum MPDL3280A Concentration (Cmax);   Score of Participant-Reported Health Status in the EuroQol 5-Dimension, 5-Level Version (EQ-5D-5L) Questionnaire
20 Unknown  Intra-arterial Chemotherapy for Spinal Metastases
Conditions: Spinal Diseases;   Spinal Metastases;   Spinal Tumors
Intervention: Drug: Melphalan (intra-arterial infusion)
Outcome Measures: Percentage of patients in whom intra-arterial chemotherapy is performed without severe complication.;   Change in spinal epidural tumor size as depicted on the MRI scans after treatment.

These studies may lead to new treatments and are adding insight into Metastases To Bladder etiology and treatment.

A major focus of Metastases To Bladder research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.


Discuss Metastases To Bladder